ReviewJournal of the National Medical Association2005
Respiratory syncytial virus bronchiolitis.
Review in Journal of the National Medical Association, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review.Influenza and other respiratory viruses · 2016Pooled it
- Comparison of nebulized epinephrine to albuterol in bronchiolitis.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2008Trial
- Review
- Review
- Monitoring influenza and respiratory syncytial virus in wastewater. Beyond COVID-19.The Science of the total environment · 2023Article
- Serious Bacterial Infections in Preterm Infants: Should Their Age Be "Corrected"?Journal of clinical medicine · 2023Article
- Detailed Molecular Interactions between Respiratory Syncytial Virus Fusion Protein and the TLR4/MD-2 Complex In Silico.Viruses · 2022Article
- Microbial Natural Products with Antiviral Activities, Including Anti-SARS-CoV-2: A Review.Molecules (Basel, Switzerland) · 2022Review
- Detailed Evolutionary Analyses of the F Gene in the Respiratory Syncytial Virus Subgroup A.Viruses · 2021Article
- Intralaryngeal application of ATP evokes apneic response mainly via acting on P2X3 (P2X2/3) receptors of the superior laryngeal nerve in postnatal rats.Journal of applied physiology (Bethesda, Md. : 1985) · 2021Article
- Clinical characteristics, predictors, and performance of case definition-Interim results from the WHO global respiratory syncytial virus surveillance pilot.Influenza and other respiratory viruses · 2020Article
- Acute bacterial sinusitis in children: an updated review.Drugs in context · 2020Review
- The Clinical Use of Stem Cell Research in Chronic Obstructive Pulmonary Disease: A Critical Analysis of Current Policies.Journal of clinical medicine research · 2018Review
- Article
- IL-2 Expression and T lymphocyte Phenotyping in Young Children Suffering from Upper Respiratory Tract Infection with Streptococcus Pyogenes.International journal of biomedical science : IJBS · 2016Article
- Viruses associated with influenza-like-illnesses in Papua New Guinea, 2010.Journal of medical virology · 2014Article
- Molecular epidemiology of respiratory viruses in virus-induced asthma.Frontiers in microbiology · 2013Review
- Severe childhood respiratory viral infections.Advances in pediatrics · 2009Review
- Bioconjugated nanoparticle detection of respiratory syncytial virus infection.International journal of nanomedicine · 2007Article
- Effectiveness of 3% hypertonic saline nebulization in acute bronchiolitis among Indian children: A quasi-experimental study.Perspectives in clinical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus, the most common cause of bronchiolitis, is the leading cause of infant hospitalization in developed countries and accounts for substantial mortality and morbidity in developing countries. Children at increased risk of developing severe bronchiolitis are those <6 weeks of age, those born prematurely and those with an underlying cardiopulmonary disorder or immunodeficiency. Approximately 80% of cases occur in the first year of life. By two years of age, virtually all children have been infected by at least one strain of the virus. Classically, respiratory syncytial virus bronchiolitis manifests as cough, wheezing and respiratory distress. The mainstay of treatment is supportive care, consisting of adequate fluid intake, antipyretics to control fever and use of supplemental oxygen if necessary. Frequent and meticulous hand-washing is the best measure to prevent secondary spread. Treatment of respiratory syncytial virus bronchiolitis beyond supportive care should be individualized. Palivizumab has been shown to be effective in preventing severe respiratory syncytial virus bronchiolitis in high-risk children when given prophylactically. In the majority of cases, the disease is usually self-limited. The mortality rate is <1% and occurs predominantly in children at high risk for severe disease.
Indexed as
Identifiers
16396064PMC2640754W2111544216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.